Trinity Biotech Announces Quarter 3 Financial Results, Acquisition of Blood Bank Screening Business and FDA Approval of HIV-2 Claim

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ireland, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2013, the acquisition of the blood bank screening business of Lab 21 and FDA approval for a claim for HIV-2 on its Unigold rapid HIV product.

Help employers find you! Check out all the jobs and post your resume.

Back to news